Inogen Inc (NASDAQ:INGN) has received a consensus recommendation of “Hold” from the eight analysts that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation, two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $113.25.
INGN has been the subject of several research analyst reports. BidaskClub cut Inogen from a “sell” rating to a “strong sell” rating in a research report on Saturday, April 13th. Needham & Company LLC dropped their price target on Inogen from $191.00 to $111.00 and set a “strong-buy” rating for the company in a research report on Wednesday, May 8th. JPMorgan Chase & Co. dropped their price target on Inogen to $175.00 and set an “overweight” rating for the company in a research report on Wednesday, February 27th. Stifel Nicolaus dropped their price target on Inogen from $160.00 to $85.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. Finally, Piper Jaffray Companies dropped their price target on Inogen from $290.00 to $185.00 and set an “overweight” rating for the company in a research report on Wednesday, February 27th.
A number of institutional investors have recently bought and sold shares of INGN. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Inogen in the 1st quarter valued at about $25,000. Fifth Third Bancorp boosted its position in Inogen by 115.0% during the 1st quarter. Fifth Third Bancorp now owns 286 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 153 shares during the period. Hanson McClain Inc. acquired a new position in Inogen during the 1st quarter worth $50,000. South Dakota Investment Council acquired a new position in Inogen during the 4th quarter worth $87,000. Finally, First Mercantile Trust Co. acquired a new position in Inogen during the 4th quarter worth $99,000. Hedge funds and other institutional investors own 98.63% of the company’s stock.
INGN stock opened at $67.67 on Tuesday. The company has a market capitalization of $1.48 billion, a PE ratio of 32.71, a PEG ratio of 2.66 and a beta of 1.58. Inogen has a twelve month low of $62.31 and a twelve month high of $287.79. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.35 and a quick ratio of 6.70.
Inogen (NASDAQ:INGN) last posted its quarterly earnings data on Tuesday, May 7th. The medical technology company reported $0.24 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.29 by ($0.05). The firm had revenue of $90.20 million during the quarter, compared to analyst estimates of $89.69 million. Inogen had a net margin of 12.56% and a return on equity of 15.59%. Inogen’s revenue was up 14.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.48 earnings per share. On average, sell-side analysts predict that Inogen will post 1.63 EPS for the current year.
Inogen Company Profile
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Read More: Gross Domestic Product (GDP)
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.